Search Results
Feb 02, 2026, 11:07 ET Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
Feb 02, 2026, 11:00 ET January's Top 10 Celebrity Real Estate News: Kylie Jenner, Sean Hannity & Zohran Mamdani
11 baths with a separate two-story guesthouse and a tennis court. The home is for sale at $39.995 million, with proceeds going to charity.Gene Hackman's Death Home For Sale
More news about: Top Ten Real Estate Deals
Feb 02, 2026, 11:00 ET Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
Feb 02, 2026, 10:00 ET ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
unique advantages in clinical speed, platform iteration, and portfolio strategy, predicting globally competitive innovations in ADC, TCE, and novel cell/gene therapies in the coming years.Cardio-Renal-Metabolic Session: Experts emphasized de-risking clinical trials and recognized small biotech as the
More news about: ACROBiosystems
Feb 02, 2026, 09:00 ET Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Committee of the World Health Organization (WHO). The USAN and INN nomenclature schemes for CAR-T cell therapies follow a two-word structure describing the gene and cell component.
More news about: Anixa Biosciences, Inc.
Feb 02, 2026, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for February 2026
Upcoming free, educational webinars from Xtalks will feature topics biomarkers, cell and gene therapy, clinical trials, drug discovery & development, pharmacovigilance and pharma manufacturing & supply chain.TORONTO, Feb.
More news about: Xtalks
Feb 02, 2026, 07:51 ET Global Times: Why is legislation needed for reading in China?
reading" and "Pass down the legacy of poetry and books across generations" have been handed down to this day. This unique cultural gene is also reflected in every line of this legislation. For example, the regulations place special emphasis on the role of "teaching by words and deeds,"
More news about: Global Times
Feb 01, 2026, 13:56 ET QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically,
More news about: Kessler Topaz Meltzer & Check, LLP
Jan 31, 2026, 20:05 ET National Inventors Hall of Fame Announces Wi-Fi and Spanx Innovators Among 2026 Class
homes and businesses. He is the co-founder of Broadcom Inc., a global leader in wired and wireless communications.Feng Zhang: CRISPR Gene EditingFeng Zhang has invented transformative technologies to improve human health, including first demonstrating the use of engineered
More news about: National Inventors Hall of Fame
Jan 30, 2026, 17:00 ET Origin Agritech Announces Fiscal Year 2025 Results
Beijing, Hainan, and HenanOrigin accumulated over 200,000 corn germplasm resourcesThe Company received authorization for multiple gene editing traits, including leaf angle, plant height, and rust resistanceFiscal Year 2025 Financial Results: For the fiscal
More news about: Origin Agritech Limited
Jan 30, 2026, 16:18 ET America's Freedom Tribute's Traveling Vietnam Wall & Cost of Freedom Tribute Returns to Coachella Valley Feb. 8, 2026
long standing 8 feet tall at its highest apex. It will be on display to the public on the tarmac behind the Palm Springs Air Museum located at 745 N. Gene Autry Trail, Palm Springs, CA 92262. Once it opens to the public on Sunday, February 8, 2026, at 10 AM, it will be open 24/7 until Wednesday morning,
More news about: Palm Springs Air Museum
Jan 30, 2026, 10:36 ET $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/flexible-requirements-cell-and-gene-therapies-advance-innovationLogo:
More news about: Equity Insider
Jan 30, 2026, 09:39 ET Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference
Conference, Ojai, California1The INFUSE study includes adults with migraine who had failed at least one preventive anti-calcitonin gene–related peptide (aCGRP) treatment1Clinically meaningful improvements reported across migraine frequency, responder rates and other
More news about: H. Lundbeck A/S
Jan 30, 2026, 09:35 ET Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference
Conference, Ojai, California1The INFUSE study includes adults with migraine who had failed at least one preventive anti-calcitonin gene–related peptide (aCGRP) treatment1Clinically meaningful improvements reported across migraine frequency, responder rates and other
More news about: H. Lundbeck A/S
Jan 30, 2026, 08:00 ET Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
evasionNuclear PD-L1 was shown to be enriched in immunotherapy-resistant tumor cells, metastatic lesions, and circulating tumor cells (CTCs), and to regulate gene programs associated with invasion, survival, and immune suppression. Importantly, this intracellular PD-L1 pool is not addressed by existing PD-1/PD-L1
More news about: Kazia Therapeutics Limited
Jan 29, 2026, 19:01 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
2026, Regenxbio issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Pomerantz LLP
Jan 29, 2026, 18:06 ET INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint
Company's announcement of topline results from its Phase 3 INFRONT-3 trial, evaluating latozinemab in individuals with frontotemporal dementia due to a gene mutation (FTD-GRN).
More news about: Levi & Korsinsky, LLP
Jan 29, 2026, 18:06 ET Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action
Regenxbio Inc. (NASDAQ: RGNX) regarding potential gaps between information provided to investors and underlying safety developments in the company's gene therapy clinical programs.
More news about: Levi & Korsinsky, LLP
Jan 29, 2026, 17:45 ET Foothill Gold Line Board Maintains Leadership in 2026
currently includes Pomona Mayor and Metro Board Member Tim Sandoval, La Verne Mayor Tim Hepburn, Montclair Mayor John Dutrey, Pasadena Council Member Gene Masuda, and South Pasadena representative Dan Evans.About the Foothill Gold Line Construction Authority – The Construction Authority
More news about: Foothill Gold Line Construction Authority
Jan 29, 2026, 15:00 ET From VMX to what's next: how NAVC is leading the future of animal health
connections, it's also about giving back. NAVC calls Orlando home, and it's our privilege to support the local community in a multitude of ways," said NAVC CEO Gene O'Neill. "As NAVC continues to grow globally, we remain intentional about showing up locally through service, partnerships and economic investment."VMX
More news about: North American Veterinary Community (NAVC)
Jan 29, 2026, 13:31 ET Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
billion metabolic syndrome opportunity with curative infrastructure rather than simple symptom management. For the smart money, these cell-based and gene-targeted therapies are officially the longevity alpha of the 2026 cycle.Avant Technologies, Inc. (OTCQB: AVAI)
More news about: USA News Group
Jan 29, 2026, 11:18 ET ISS National Lab Marks Record Year for Space-Based Scientific Results
and with greater uniformity than comparable cultures on Earth, which may take months to self-assemble. These results enable faster testing of novel gene therapies for neurological diseases.
More news about: International Space Station National Lab
Jan 29, 2026, 08:00 ET NanoMosaic Secures FDA Advanced Manufacturing Technology (AMT) Designation for Advanced Gene Therapy Analytics
Gene therapy developers and manufacturers adopting NanoMosaic's platform gain access to enhanced FDA engagement and expedited IND/BLA review.The FDA AMT designation verifies NanoMosaic platform's ability to enhance efficiency, product quality, and scalability across AAV gene therapy
More news about: NanoMosaic
Jan 29, 2026, 08:00 ET PurposeBuilt Brands Expands Horizon Big Partnership to Agency of Record, Unifying National and Retail Media Strategy to Continue Driving Growth
affinity, purchase frequency, and lifetime value."PurposeBuilt understands that shopping discovery now happens everywhere, all at once," said Gene Turner, President Global Chief Client Officer, Horizon Media. "Brands are operating in an environment where 62% of consumers use ChatGPT or Google Gemini
More news about: Horizon Media
Jan 29, 2026, 04:00 ET LifeArc Ventures 2025: New geographies and investments, a growing team and continued portfolio progress
exclusive option and license agreement: AviadoBio secured an option to worldwide rights (ex-Greater China) to UGX-202, an advanced optogenetics gene therapy for retinitis pigmentosa and retinal diseases, currently in Phase 1. The deal includes up to $413 million in milestones and royalties.
More news about: LifeArc